Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugsCNBC • 03/31/26
Eli Lilly To Buy Centessa Pharma For Up To $7.8 Billion; Centessa Shares SkyrocketInvestors Business Daily • 03/31/26
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli LillyCNBC • 03/31/26
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPRNewsWire • 03/31/26
Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.Barrons • 03/30/26
Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico PartnershipInvestopedia • 03/30/26
Eli Lilly teams up with Insilico to accelerate AI-powered drug developmentProactive Investors • 03/30/26
Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment, FT reportsReuters • 03/30/26
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global marketCNBC • 03/29/26
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT saysReuters • 03/29/26
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesityPRNewsWire • 03/28/26
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitisPRNewsWire • 03/27/26